RE:IF we are talking about "patent challenge"/Epidiolex, THENDon't forget about Sativex approved in Europe, JAZZ's other 98% pure CBD nasal spray pharmaceutical....different countries regulatory bodies have different dates for patent challenges and exclusivity rights....a generic may be offered in one country but not in another... non-disclosure agreements with "Traditional Pharmaceutical Companies" would only be for commercialization purposes because clinical trial data is within the public realm...clearly the "entry into the U.S market" through the FDA masterfile has commercialization aspirations/partnerships/NDA's...it doesn't sound to me like they're simply getting the certification to wait by the phone for a pharmaceutical client. I certainly wouldn't want ANYBODY to purchase shares based on my commentary, I do enjoy the hunt for knowledge pertaining to these possibilities which is why I bring it to public discussion.